| Vol. 13.01 – 11 January, 2022 |
| |
|
|
| Scientists reported the first large-scale genome-wide association study on blood CD34+ cell levels. Across 13,167 individuals, they identified 9 significant and 2 suggestive associations, accounted for by 8 loci. [Blood] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators used single-cell full-length transcriptome data to construct an isoform-based transcriptional atlas of the murine endothelial-to-HSC transition, which enabled the identification of hemogenic signature isoforms and stage-specific alternative splicing events. [Science Advances] |
|
|
|
| The authors showed that STK35 and PDIK1L function catalytically and redundantly in the same pathway as SCP4 to maintain acute myeloid leukemia proliferation and to support amino acid biosynthesis and transport. [Cell Reports] |
|
|
|
| Co-treatment with SNDX-50469 and BCL2 inhibitor, or CDK6 inhibitor induced synergistic lethality in cell lines and patient-derived AML cells harboring MLL1-r or mutant NPM1. [Blood Cancer Journal] |
|
|
|
| Researchers identified an important role of the deubiquitylase ubiquitin-specific protease-12 (USP12) in pro-survival autophagy and resultant bortezomib resistance in multiple myeloma by stabilizing high mobility group box-1 (HMGB1). [Oncogene] |
|
|
|
| The authors investigated the effects of exosomes derived from bone marrow mesenchymal stem cells on the regulation of acute myeloid leukemia and the underlying mechanisms mediated by microRNA. [Journal of Nanobiotechnology] |
|
|
|
| Scientists demonstrated that CCND3 was essential for the proliferation and survival of B cell acute lymphoblastic leukemia, independent of the mutational background. [Oncogenesis] |
|
|
|
| Researchers presented a new strategy to identify chemicals that are likely to promote a desired phenotype. They tested the in vitro differentiation potential of candidate compounds using the HL-60 human cell line as a myeloid differentiation model. [Cell Death Discovery] |
| |
|
|
| The authors defined the prevalence and variation of CHIP over time and assessed the influence on clinical inflammation syndromes, cytopenia and outcome. [Blood Advances] |
|
|
|
| The impacts of differential r/r B-ALL tumor burdens on the clinical therapeutic efficacy and safety profiles after ssCART-19 cell treatment were analyzed. [Scientific Reports] |
|
|
|
|
| The authors report on mechanism of action, safety, and efficacy data on combination strategies based on hypomethylating agents in the setting of post-allogeneic stem cell transplant relapse. [Frontiers in Oncology] |
|
|
|
| Scientists discuss different generations, challenges, and clinical studies related to chimeric antigen receptor (CAR) T cells for ALL treatment. [Cancer Gene Therapy] |
|
|
|
|
| Starton Therapeutics, Inc. announced that it has received its first Clinical Trial Authorization in the Netherlands to initiate a Phase I study evaluating STAR-LLD, a continuous delivery lenalidomide in development to expand the standard of care for the most common blood cancers, bioavailability. [Starton Therapeutics, Inc.] |
|
|
|
| AlloVir, Inc. announced that the US FDA has granted its lead multi-virus specific T cell therapy, posoleucel, RMAT designation for the treatment of AdV infection following allogeneic hematopoietic stem cell transplant. The designation is based on positive results from the Phase II CHARMS study. [AlloVir, Inc.] |
|
|
|
|
| February 10 – 12, 2022 Lorne, Victoria, Australia |
|
|
|
|
|
| RWTH Aachen Medical School – Aachen, Germany |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| Memorial Sloan Kettering – New York City, New York, United States |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
|